Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Azadyne logo — Treating Autoimmune disease.

Azadyne

Treating Autoimmune disease.

Founded 2016 United Kingdom Canterbury, United Kingdom 3 employees Series Unknown Total: $1.75M Health Care

General Information

Company Name Azadyne
Founded Year 2016
Location United Kingdom Canterbury, United Kingdom +1
Founders / Decision Makers
Team member
Employees 3
Industries Health Care
Funding Stage Series Unknown
Social

Get notified when Azadyne moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Azadyne

Azadyne is a pharma R&D company based in the United Kingdom that focuses on developing improved medicines for patients with autoimmune diseases, primarily Multiple Sclerosis. The company's roots can be traced back to the research conducted by Profs Vincent P. Kelly, Stephen Connon, and J. Mike Southern at Trinity Biomedical Sciences Institute, Trinity College Dublin. Autoimmune diseases, which include conditions such as Multiple Sclerosis, Rheumatoid Arthritis, and Inflammatory Bowel Disease, are chronic and currently incurable conditions resulting from the body mistakenly attacking itself, leading to inflammation and damage. Azadyne's innovative approach revolves around harnessing the potential of a naturally occurring micronutrient called queuine to control the autoimmune response in the body. The company has made significant strides in the development of new molecules that promise improved therapeutic outcomes for patients and their families. Azadyne's candidates are progressing towards Phase I or FIH trials, showcasing their commitment to bringing practical solutions to the market. Having been founded in 2016, Azadyne secured a Venture Round investment on 03 September 2020, with Renaissance Capital Partners as the supporting investors. Their dedication to addressing unmet medical needs in the field of autoimmune diseases positions Azadyne as a promising venture in the Health Care industry, with the potential to make a significant impact in the pharmaceutical landscape.

Taxonomy: Pharmaceutical Research & Development, Autoimmune Disease, Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Biomedical Sciences, Drug Development, Trinity College Dublin, Queuine, Inflammation, Chronic Diseases, Phase I Trials, FIH Trials, Novel Chemistry, Therapeutic Outcomes

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 1 •••• •••• 03 Sep 2020
Seed Round •••••• 1 •••• •••• 27 Mar 2019
Seed Round •••••• 1 •••• •••• 18 Feb 2019

Azadyne Alternatives & Competitors

Azadyne vs
Octave
Octave United States

Your partner in precision care for multiple sclerosis (MS) and beyond.

Grant
88 employees
Biotechnology, Health Care
Azadyne vs
Cyxone
Cyxone Sweden

Life-changing treatments for disorders of the immune system

11 employees
Biotechnology, Health Care
Azadyne vs
Nuvig Therapeutics
Nuvig Therapeutics

Pioneering Autoimmune Therapies for a New Standard of Care.

FAQ About Azadyne

Treating Autoimmune disease.
Azadyne was founded in 2016.
Azadyne is headquartered in Canterbury, United Kingdom.
Azadyne operates in the following industries: Health Care.
Azadyne has approximately 3 employees.
Azadyne has completed 3 funding rounds, raising a total of $1.75M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Azadyne include Octave, Cyxone, Nuvig Therapeutics, Revolo Biotherapeutics, Qynapse. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Azadyne and Octave are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Azadyne and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes